Neuroprotection and glatiramer acetate: the possible role in the treatment of multiple sclerosis.
D000818:Animals; D001369:Axons / Q000473:pathology; D019208:Brain-Derived Neurotrophic Factor / Q000378:metabolism; D003711:Demyelinating Diseases / Q000150:complications / Q000188:drug therapy / Q000473:pathology / Q000503:physiopathology; D000068717:Glatiramer Acetate; D049673:History, 20th Century; D006801:Humans; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology / Q000517:prevention & control; D019636:Neurodegenerative Diseases / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control; D018696:Neuroprotective Agents / Q000266:history / Q000494:pharmacology / Q000627:therapeutic use*; D010455:Peptides / Q000266:history / Q000494:pharmacology / Q000627:therapeutic use*
D019208:Brain-Derived Neurotrophic Factor; D018696:Neuroprotective Agents; D010455:Peptides; D000068717:Glatiramer Acetate